Skip to main content
European Commission logo print header

A paradigm for the establishment of new prognostic markers for common cancers: protease systems as indicators of invasive potential.


A rational approach to focused adjuvant therapy is urgently needed in the management of patients suffering from the most common cancers; the ability to identify patients at high risk would enable most cost-effective use of the treatments available. This proposal assembles a collaborative effort from seven leading European cancer research laboratories to identify new prognostic marker sets based on a systematic exploration of tissue protease systems functionally involved in tumour progression. The partners will apply state of the art molecular biology to identify the most relevant novel proteases, before embarking upon their quantitative measurement in large collections of patient material. The clinical studies for assessment of prognostic significance will examine the prognostic significance of each marker and derive marker sets, which optimise prognostic power. Commercially attractive kits will be assembled for the new marker sets.

Call for proposal

Data not available


Stransboulevarden 49
2100 Koepenhagen

See on map

EU contribution
€ 0,00

Participants (6)